Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).

Article  PubMed  Google Scholar 

Polkinghorn, W. R. et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 3, 1245–1253 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang, K.-H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728–13733 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

Article  CAS  PubMed  Google Scholar 

Chang, K.-H. et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154, 1074–1084 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465–2474 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).

Article  CAS  PubMed  Google Scholar 

Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487–495 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563–577 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489.e476 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamada, Y. & Beltran, H. Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep. 23, 15 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).

Article  CAS  PubMed  Google Scholar 

Hofman, M. S. et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 19, 825–833 (2018).

Article  CAS  PubMed  Google Scholar 

Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797–804 (2021).

Article  CAS  PubMed  Google Scholar 

Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 23, 1389–1397 (2022).

Article  CAS  PubMed  Google Scholar 

Chow, K. M. et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur. Urol. 84, 36–48 (2023).

Article  PubMed  Google Scholar 

Pienta, K. J. et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J. Urol. 206, 52–61 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 77, 403–417 (2020).

Article  PubMed  Google Scholar 

Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA–PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).

Article  CAS  PubMed  Google Scholar 

Sartor, O. et al. LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann. Oncol. 34, S1324–S1325 (2023).

Article  Google Scholar 

Bakht, M. K. et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr. Relat. Cancer 26, 131–146 (2019).

Article  CAS  Google Scholar 

Bakht, M. K. et al. Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for 18F-FDG imaging of PSMA-suppressed tumors. J. Nucl. Med. 61, 904–910 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bakht, M. K. et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat. Cancer 4, 699–715 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sayar, E. et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight 8, e162907 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016).

Article  CAS